Drop in testosterone tied to prostate cancer recurrence
Men whose testosterone drops following radiation therapy for prostate cancer are more likely to experience a change in PSA levels that signals their cancer has returned, according to new research from Fox Chase Cancer Center. The findings will be presented on October 29 at the American Society for Radiation Oncology's 54th Annual Meeting.
Specifically, men whose testosterone fell following various forms of radiation therapy were more likely to experience an increase in prostate-specific antigen (PSA)—often the first indication the cancer has recurred.
"The men who had a decrease in testosterone also appear to be the men more likely to see an increase in PSA after treatment," says study author Jeffrey Martin, MD, resident physician in the Department of Radiation Oncology at Fox Chase.
In theory, doctors may one day be able to use testosterone levels to guide treatment decisions, says Martin. "For men with a decrease in testosterone, doctors might intervene earlier with other medications, or follow their PSA more closely than they would otherwise, to spot recurrences at an earlier time."
Martin and his colleagues decided to conduct the study because there is limited information regarding testosterone levels after radiation treatment and what it means for prognosis. To investigate whether a decrease in testosterone has any clinical effects, Martin and his colleagues reviewed medical records from nearly 260 men who received radiation therapy for prostate cancer between 2002 and 2008. The men were treated with either brachytherapy, in which doctors insert radioactive seeds in the prostate, or intensity modulated radiation therapy (IMRT), in which an external beam of radiation is directed at the prostate.
The researchers found that testosterone levels tended to decrease following both forms of radiation therapy. And men who experienced a post-radiation drop in testosterone— particularly a significant drop—were more likely to see their PSA levels rise during the follow-up period.
Still, an increase in PSA—known as biochemical failure—was relatively rare, the authors found. "Only 4% of patients with low-risk prostate cancer had biochemical failure at five years," says Martin.
Even though researchers have seen testosterone decrease following another form of radiation, these latest findings are still somewhat surprising, says Martin, because testosterone is believed to drive prostate cancer. In fact, some patients with advanced forms are prescribed hormone therapy that attempts to knock down testosterone.
"Seeing that a drop in testosterone is tied to recurrence is kind of a surprising result," says Martin. "We don't necessarily know what this means yet. I think the relationship between testosterone levels following radiation therapy and prognosis needs more study, and until then it's premature to say this is something patients should ask their doctors about."
This was a small study that needs to be validated in a larger group of men before doctors begin basing their predictions of recurrence on patients' testosterone levels, he cautions. "I think the link between testosterone and PSA needs more study, in a larger set of patients."
Provided by Fox Chase Cancer Center
- Testosterone therapy does not up prostate cancer incidence Jun 15, 2012 | not rated yet | 0
- Study suggests another look at testosterone-prostate cancer link Apr 19, 2011 | not rated yet | 0
- Undetectable PSA after radiation is possible and predicts good patient outcomes Nov 02, 2009 | not rated yet | 0
- More testosterone increases prostate cancer risk in older men: study Jul 26, 2012 | not rated yet | 0
- Radiation added to hormone therapy increases survival for men with prostate cancer Sep 22, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
6 hours ago Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
Aggressive forms of bladder cancer involve the protein PODXL – a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.
Cancer 1 hour ago | 5 / 5 (1) | 0
For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized ...
Cancer 2 hours ago | 5 / 5 (1) | 0 |
More than half of patients diagnosed with Non-Hodgkin Lymphoma (NHL) are now surviving the disease thanks to improved diagnosis and treatment, according to a new report1 from Cancer Research UK.
Cancer 2 hours ago | 5 / 5 (1) | 0
(Medical Xpress)—Researchers at the University of Virginia School of Medicine have identified a promising target for treating glioblastoma, one that appears to avoid many of the obstacles that typically frustrate efforts ...
Cancer 3 hours ago | 3.5 / 5 (2) | 0 |
(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.
Cancer 17 hours ago | not rated yet | 0
A potentially ground-breaking human drug trial is currently underway, which aims to discover whether blood pressure medication can slow or halt the progression of Alzheimer's Disease (AD). This is the latest ...
3 minutes ago | not rated yet | 0
Scientists at Newcastle University have shed new light on how the brain tunes in to relevant information.
1 hour ago | 5 / 5 (1) | 0 |
Professor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, was part of an international team that discovered the previously unknown pathway of how the bacterium colonizes people.
1 hour ago | 5 / 5 (1) | 0 |
(Medical Xpress)—Research by U of T Mississauga psychology professor Glenn Schellenberg reveals that two key personality traits – openness-to-experience and conscientiousness—predict better than IQ ...
1 hour ago | not rated yet | 0 |
Studying the networks of connections in the brains of people affected by schizophrenia, bipolar disease or depression has allowed Dr. Peter Williamson, from Western University, to gain a better understanding of the biological ...
1 hour ago | not rated yet | 0
New techniques in imaging of brain activity developed by Jean Gotman, from McGill University's Montreal Neurological Institute, and his colleagues lead to improved treatment of patients suffering from epilepsy. The combination ...
1 hour ago | not rated yet | 0